Glenmark Claims Lead In New Pain Management Compound; Files For Multiple Patents
This article was originally published in PharmAsia News
MUMBAI - Inspired by major out-licensing deals with companies including Eli Lilly and more recently Sanofi-Aventis for research in pain management drugs in the transient receptor potential (TRP) class, India's Glenmark Pharmaceuticals has beefed up its presence in this category by announcing discovery of yet another novel chemical entity, coded GRC 17536
You may also be interested in...
Glenmark’s Pain Drug Fails To Meet Primary Endpoint, Path Of Another Altered By Sanofi
Indian drug maker Glenmark disclosed that Sanofi shelved research on one of its compounds and altered the indication of another biologic for multiple sclerosis treatment.
"We Have Gone Through Hardships But Our Passion Remains High," Says Glenn Saldanha, Managing Director, Glenmark Pharma: An Interview With PharmAsia News (Part 2 of 2)
Glenn Saldanha, Managing Director, Glenmark Pharmaceuticals has been speaking about discovery research in India for more than a decade but his critics from bigger companies played down those efforts as high decibel talk, over-ambitious thoughts and a few even called them day dreaming moves. But five out-licensing deals in seven years with companies like Eli Lilly, Merck Serono and Sanofi-Aventis have transformed the way Glenmark Pharma is seen by the world today (PharmAsia News, May 3, 2010).
Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities
MUMBAI - An extensive worldwide search for novel agents to treat chronic neuropathic pain has brought together Sanofi-Aventis and Indian drug maker Glenmark Pharma through a development and commercialization deal for transient receptor potential vanilloid (TRPV3) antagonist molecules